《新股表現》沛嘉醫療(09996.HK)暗盤高開63%報25元
根據輝立交易平台顯示,明天掛牌的沛嘉醫療(09996.HK)暗盤高開63%報25元,最高見26.2元,最低見24元,現造24.4元,較上市價15.36元,高59%,成交241萬股。
沛嘉專注於中國高增長的介入手術醫療器械市場,且為中國各經導管瓣膜治療醫療器械市場及神經介入手術醫療器械市場中的領先內地參與者。是次以每股15.36元來港上市合共發售約1.525億股,其中10%公開發售獲逾1,183.4倍超購,已啟動回撥機制佔比增至50%,認購一手中籤率僅8.5%;料集資淨額約22億元,主要用作開發和商業化公司核心產品TaurusOne及其他主要在研產品、為其他在研產品正在進行臨床試驗、準備註冊備案及潛在商業化推出提供資金、加強研發能力及用作潛在戰略收購等。上市聯席保薦人分別為大摩及華泰國際。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.